Table 2

Impact of HLA mismatches in allele level on relapse

All diseases
nHR (95% CI)P
HLA-A matched 4018 1.00 (ref)  
HLA-A 1 allele mismatched 597 1.00 (0.82-1.22) .99 
HLA-A 2 alleles mismatched 28 0.79 (0.28-2.28) .67 
HLA-B matched 4351 1.00 (ref)  
HLA-B 1 allele mismatched 288 1.06 (0.79-1.41) .7 
HLA-B 2 alleles mismatched* ND ND 
HLA-C matched 3308 1.00 (ref)  
HLA-C 1 allele mismatched 1212 0.68 (0.58-0.80) <.001 
HLA-C 2 alleles mismatched 123 0.43 (0.24-0.75) .003 
HLA-DRB1 matched 3718 1.00 (ref)  
HLA-DRB1 1 allele mismatched 866 0.93 (0.74-1.18) .56 
HLA-DRB1 2 alleles mismatched 59 1.18 (0.53-2.63) .68 
HLA-DQB1 matched 3597 1.00 (ref)  
HLA-DQB1 1 allele mismatched 958 1.12 (0.90-1.40) .30 
HLA-DQB1 2 alleles mismatched 88 0.73 (0.35-1.52) .40 
HLA-DPB1 matched 1584 1.00 (ref)  
HLA-DPB1 1 allele mismatched 2190 0.80 (0.70-0.92) .002 
HLA-DPB1 2 alleles mismatched 869 0.62 (0.51-0.75) <.001 
All diseases
nHR (95% CI)P
HLA-A matched 4018 1.00 (ref)  
HLA-A 1 allele mismatched 597 1.00 (0.82-1.22) .99 
HLA-A 2 alleles mismatched 28 0.79 (0.28-2.28) .67 
HLA-B matched 4351 1.00 (ref)  
HLA-B 1 allele mismatched 288 1.06 (0.79-1.41) .7 
HLA-B 2 alleles mismatched* ND ND 
HLA-C matched 3308 1.00 (ref)  
HLA-C 1 allele mismatched 1212 0.68 (0.58-0.80) <.001 
HLA-C 2 alleles mismatched 123 0.43 (0.24-0.75) .003 
HLA-DRB1 matched 3718 1.00 (ref)  
HLA-DRB1 1 allele mismatched 866 0.93 (0.74-1.18) .56 
HLA-DRB1 2 alleles mismatched 59 1.18 (0.53-2.63) .68 
HLA-DQB1 matched 3597 1.00 (ref)  
HLA-DQB1 1 allele mismatched 958 1.12 (0.90-1.40) .30 
HLA-DQB1 2 alleles mismatched 88 0.73 (0.35-1.52) .40 
HLA-DPB1 matched 1584 1.00 (ref)  
HLA-DPB1 1 allele mismatched 2190 0.80 (0.70-0.92) .002 
HLA-DPB1 2 alleles mismatched 869 0.62 (0.51-0.75) <.001 

Each group was compared with the matched group in each locus after adjusting for other matching status of HLA, sex (donor-recipient pairs), patient age (linear), donor age (linear), type of disease, risk of leukemia relapse (standard, high, and diseases other than leukemia), GVHD prophylaxis (CSP vs FK), ATG vs no ATG), and preconditioning (TBI vs non-TBI).

ref indicates reference; and ND, not determined.

*

Comprehensive analysis could not be performed due to the small number of cases.

Close Modal

or Create an Account

Close Modal
Close Modal